These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35392050)

  • 1. Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).
    Tsivgoulis G; Deftereos S; Gobbi C; Gulowsen Celius E; Kulakowska A; Maniscalco G; Mendes I; Grigoriadis N
    J Cent Nerv Syst Dis; 2022; 14():11795735211069441. PubMed ID: 35392050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D; Müller B; Übler S
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study.
    Borriello G; Chisari CG; Maimone D; Mirabella M; Paolicelli D; Assogna F; Caradonna S; Patti F
    Front Neurol; 2024; 15():1422078. PubMed ID: 39114529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    Manni A; Oggiano F; Palazzo C; Panetta V; Gargano CD; Mangialardi V; Guerra T; Iaffaldano A; Caputo F; Iaffaldano P; Ruggieri M; Trojano M; Paolicelli D
    J Neurol Sci; 2024 Jul; 462():123070. PubMed ID: 38850773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.
    Filippi M; Ferrè L; Zanetta C; Rizzi C; Pessina G; Assogna F; Rocca MA
    Front Neurol; 2024; 15():1379712. PubMed ID: 38638312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.
    Sguigna PV; Hussain RZ; Okai A; Blackburn KM; Tardo L; Madinawala M; Korich J; Lebson LA; Kaplan J; Salter A; Manouchehri N; Stuve O
    Ther Adv Neurol Disord; 2024; 17():17562864241233858. PubMed ID: 38585373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
    Moser T; Ziemssen T; Sellner J
    Wien Med Wochenschr; 2022 Nov; 172(15-16):365-372. PubMed ID: 35451662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
    Santos M; Sequeira J; Abreu P; Guerreiro R; Santos M; Ferreira J; Brum M; Ladeira F; Leitão L; Dias R; Sá MJ; Salgado V; Capela C; de Sá J
    Clin Neuropharmacol; 2023 May-Jun 01; 46(3):105-111. PubMed ID: 37191564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.